

Investor Presentation

April 2023



Forward Looking Statement

This release contains forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, forecasts, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. The Company makes no express or implied representation or warranty as to the completeness of forward-looking statements or, in the case of projections, as to their attainability or the accuracy and completeness of the assumptions from which they are derived. Factors that could cause actual results to materially differ from forwardlooking statements include, but are not limited to, the need to obtain CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement for our products from health insurance companies, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the impact of COVID-19 on the global economy and other risks described in our filings with the Securities and Exchange Commission including, but not limited to our Annual Report on Form 10-K for the year ended December 31, 2022 as well as our quarterly reports on Form 10-Q and current reports on Form 8-K. Any forward-looking statement made by us in this release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forwardlooking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.



Investment Highlights



At-Home Prescription Strength Electrotherapy Pain Management Leader



Robust and Durable Business Model with High Recurring Revenue



Pipeline Products: Hemodynamic/Fluid Volume Monitor, Laser-based Noninvasive CO-Oximeter & Total Hemoglobin Pulse Oximeter, and Sepsis Monitor



History of Consistent Operational Execution



Strong Financial Performance with >\$150M in Annual Revenue, 20%+ YoY Revenue Growth, ~80% Gross Margins, and 7+ years of Consistent Profitability

Total Addressable Market



- Over 1.5 billion worldwide suffering from chronic pain¹
- 84% of patients were able to reduce medication use²

>6,000 hospitals and >900,000 staffed beds in the U.S.³

• Over 36M annual hospitals admissions in the U.S.³

- 1) Global Industry Analysts, Inc. (2011) Global Pain Management Market to Reach US\$60 Billion by 2015, According to a New Report by Global Industry Analysts, Inc. http://www.prweb.com/pdfdownload/8052240.pdf
- 2) Chabal, et. al. Long-Term Transcutaneous Electrical Nerve Stimulation (TENS) Use: Impact on Medical Utilization and Physical Therapy Costs Clinical Journal of Pain. The Clinical Journal of Pain. Vol 14, No 1. March 1998
- 3) The American Hospital Association Fast Facts on U.S. Hospitals, 2021

Total Addressable Market Electrotherapy

\$900M Pain & Rehabilitation Incontinence Treatment Stroke Rehab

ELECTROTHERAPY



InWave

Incontinence Treatment





NeuroMove

Stroke Rehabilitatior



NexWave

Prescription Strength Electrical Nerve Stimulation

Indications

© 2023 Zvnex. Inc.

- Relieves pain, augments healing, alleviates swelling through increased blood circulation, prevents muscle disuse atrophy, relaxes muscle spasms
- Superior performance to over-the-counter TENS devices, inferential efficacy

Capital/Consumable Business Model

- 2022: 72% of revenue from supplies

Reimbursed by Health Insurance

- Requires a prescription

Alternative to Traditional Prescription Pain Treatment

- Only 23% of patients with chronic pain found opioids "very effective"¹
- 51% of people feel that they have no control over their pain²
- 84% of patients were able to reduce medication use³
- Nearly half reduced medication consumption by 50%³
- Patients decreased the cost of medication by 50%³



- 2) American Academy of Pain Medicine (2017) AAPM Facts and Figures on Pain. http://www.painmed.org/patientcenter/facts_on_pain.aspx
- 3) Chabal, et. al. Long-Term Transcutaneous Electrical Nerve Stimulation (TENS) Use: Impact on Medical Utilization and Physical Therapy Costs Clinical Journal of Pain. The Clinical Journal of Pain. Vol 14, No 1. March 1998








Stages of Treatment Options for Chronic Pain



Limited effect in patients with moderate to severe pain Can cause mental and physical side effects and extremely addictive Must be performed by a physician and relief is typically temporary (nerve blocks/epidurals) Performed by surgeon in a hospital or surgery center



Building a Strong Distribution Network





Commercial Infrastructure: Pain Management Division

Grow Proven Direct Sales Team

Sales management, national account coverage, direct reps

- Total of 800 territories of equal revenue potential
- ≈ 460 direct sales reps at end of 1Q23
- Emphasis on recruitment of productive reps and maintaining high performing existing sales teams, top and bottom-line growth is achievable without dramatic increases in rep count

Direct Sales Productivity

- Development of focused training program designed for reps to achieve long-term productivity
- Emphasis on high-performing efficiency to grow EBITDA and Operating Profit margin
- Top performing sales representatives can ultimately produce \$2M+ in annual revenue





Growth Objectives

Increase Sales Force and Improve Productivity

- ~460 direct sales reps
- Fill out 800 sales territories
- Productivity improvements to strengthen EBITDA margins



- Expand recurring revenue base to greater than 75%
- Recurring revenue primarily from supplies (electrodes/batteries) and leased devices

Generate Consistent Net Earnings and Positive Free Cash Flow

Ð

- Sustain growth with scaled sales force
- Leverage reimbursement, regulatory and manufacturing staff
- Capital efficiency improvements in supply chain and disruption

Drive Value Through Organic Growth and M&A

- Launch new products in hot/cold therapy, cervical traction and LSO/back braces
- Drive market adoption of differentiated monitoring solutions
- Increase international sales footprint and revenues through distributors and new product approvals
- Pursue strategic add-ons with complementary product lines



Total Addressable Market Patient Monitoring

\$3.7B Hemodynamic Monitoring Pulse Oximetry Sepsis

PATIENT MONITORING



CM-1500/1600

Noninvasive Wireless Fluid Monitoring System





NiCO[™] & HemeOx[™]

Laser-based Noninvasive CO-Oximeter (*NiCO*[™]) & Total Hemoglobin Pulse Oximeter (HemeOx[™]) *prototypes **Sepsis** Noninvasive Sepsis Monitor *utility patent filed



Patient Monitoring

One Monitoring Platform

Hemodynamic Fluid Monitoring System (CM-1500 & CM-1600)


• Early warning of deteriorating fluid imbalance targeted at solving perioperative hypovolemia and fluid imbalance

Laser-based Pulse Oximetry

- NiCO[™] CO-Oximeter uses laser technology to noninvasively measure and monitor four crucial hemoglobin species with unprecedented accuracy
- HemeOx[™] Total Hemoglobin (tHb) Pulse Oximeter replaces invasive blood draws with continuous noninvasive monitoring of oxygen saturation, tHb/HCT, and O2ct

Sepsis Monitor

 Early warning of deteriorating patient condition to indicate and predict the onset of sepsis replacing current complex protocols through proactive detection and alerting





Hemodynamic Monitoring CM-1500 & CM-1600



Early warning

- Determine changing trend in patient condition, enabling earlier condition intervention

Noninvasive, continuous fluid monitoring

- Hemorrhagic Shock
- Hypovolemia
- Hypervolemia

CM-1500 FDA 510(k) cleared – February 2020


CM-1600 next generation, wireless device

- 510(k) application filed December 2021
- CE mark in process

Multiple studies enrolled in 2022 and planned for 2023



Pulse Oximetry



* Company estimates based on public industry sources



Pulse Oximetry Laser Based Technology - <u>Unprecedented Accuracy</u>

NiCOTM Noninvasive CO-Oximeter uses laser technology to measure and monitor all four hemoglobin species with unprecedented accuracy* regardless of skin pigmentation

 Direct replacement for conventional pulse oximeter monitors that utilize LED technology and fail to capture accurate reflection of patient health

HemeOxTM Total Hemoglobin (tHb) Pulse Oximeter replaces invasive blood draws with continuous noninvasive monitoring of oxygen saturation, tHb/HCT, and O2ct

 Eliminates need for tens of millions of blood draws on patients every year

*Pologe JA, Arnold DH, Delianides TP. Multi-analyte calibration and verification of a multi-parameter laser-based pulse oximeter. J Clin Monit Comput. 2021 Apr 19. doi: 10.1007/s10877-021-00704-1.

KEY PARAMETERS

O₂Hb - oxygenated hemoglobin RHb - reduced hemoglobin COHb - carboxyhemoglobin metHb - methemoglobin Pulse rate & perfusion index


KEY PARAMETERS tHb – total hemoglobin HCT – hematocrit O₂ct – oxygen content SpO₂ – oxygen saturation Pulse rate & perfusion index




Pulse Oximetry

LED vs Laser Based Technology: In Vitro Calibration Study Data*

- Oxygen Saturation: "5th Vital Sign"
- LED Technology: 35+ years old
- Pigmentary Bias in LED Pulse Ox
- Laser: Unprecedented Accuracy
- Current Pulse Oximeters overestimate SpO₂ in darkly pigmented patients and in cases of CO poisoning



*Pologe JA, Arnold DH, Delianides TP. Multi-analyte calibration and verification of a multi-parameter laser-based pulse oximeter. J Clin Monit Comput. 2021 Apr 19. doi: 10.1007/s10877-021-00704-1.



"Reference" refers to the gold standard invasive measurements performed on an OSM3 Laboratory CO-Oximeter



Sepsis Monitoring



Global Health Concern

- 48M cases and 11M deaths per year, globally*
- 1.7M cases in the US and nearly 300,000 deaths per year*
- Low survival rates

Simplified Early Detection and Alerting

- Current methods insufficient in early detection and alerting of sepsis onset
- Prevalence of sepsis partially due to the challenging nature of early diagnosis


Utility Patent Filed

- December 2021

* Company estimates based on public industry sources



Financial Performance



Highlights 7 Consecutive Years of Profitability 49% CAGR 2018-2022


> Q1 '23 Revenue: \$42.2M Q1 '23 Diluted EPS: \$0.04 Q1 '23 YoY Growth: 36%

FY 2022

Gross Margins: 80% Revenue: \$158.2M EBITDA: \$28.1M Diluted EPS: \$0.44 Cash From Operations: \$13.7M




Financial Performance Diluted Quarterly EPS (\$)





Financial Performance

Adjusted Quarterly EBITDA (\$M)



Note: Adjusted EBITDA reflects earnings before interest, taxes, depreciation, amortization, non-cash lease expense, non-cash lease expense, one-time severance, other income/expense and stock compensation. Depreciation does not include amounts related to units on lease to third parties which are depreciated and included in cost of goods sold. See appendix for EBITDA reconciliation figures



Management Team



THOMAS SANDGAARD

FOUNDER, CHAIRMAN AND CHIEF EXECUTIVE



DAN MOORHEAD

CHIEF FINANCIAL OFFICER



ANNA LUCSOK

CHIEF OPERATING OFFICER



DONALD GREGG

VP, ZYNEX MONITORING SOLUTIONS



STEVE FOX

VP, SALES



Investment Highlights



At-Home Prescription Strength Electrotherapy Pain Management Leader



Robust and Durable Business Model with High Recurring Revenue



Pipeline Products: Hemodynamic/Fluid Volume Monitor, Laser-based Noninvasive CO-Oximeter & Total Hemoglobin Pulse Oximeter, and Sepsis Monitor



History of Consistent Operational Execution



Strong Financial Performance with >\$150M in Annual Revenue, 20%+ YoY Revenue Growth, ~80% Gross Margins, and 7+ years of Consistent Profitability





Investor Relations

Gilmartin Group 650 5th Ave. Suite 2720 New York, NY 10019 <u>ir@zynex.com</u>

Company Contact

Zynex Inc. 9655 Maroon Circle Englewood, CO 80012 <u>www.zynex.com</u>



© 2023 Zynex, Inc.

Appendix

Use of Non-GAAP Financial Measures

This presentation includes the non-GAAP financial measure of Adjusted EBITDA, which differs from financial measures calculated in accordance with accounting principles generally accepted in the U.S. (GAAP). Adjusted EBITDA in this release represents net income plus interest expense, tax expense, depreciation, amortization, other income/expense, non-cash lease expense, restructuring/severance and stock compensation. The Company's management believes this non-GAAP financial measure is useful to investors and lenders in evaluating the overall financial health of the Company in that it allows for greater transparency of additional financial data routinely used by management to evaluate performance. Adjusted EBITDA can be useful for investors or lenders as an indicator of available earnings. Non-GAAP financial measures should not be considered in isolation from or as an alternative to the financial information prepared in accordance with GAAP. The following is a reconciliation of GAAP to Non-GAAP financial measures provided in this presentation.



EBITDA Reconciliation - 2023

	For The Three Months Ended March 31,				
		2023		2022	
Adjusted EBITDA:					
Net Income (Loss)	\$	1,569	\$	1,377	
Depreciation and Amortization*		423		396	
Stock-based compensation expense		307		589	
Interest expense and other (gain), net		(1,318)		(76)	
Non-cash lease expense**		-		183	
Income tax expense		33		605	
Adjusted EBITDA	\$	1,014	\$	3,074	
% of Net Revenue		2%		10%	

EBITDA Reconciliation - 2022

	F	For The Three Months Ended March 31,			
		2022	2	2021	
Adjusted EBITDA:					
Net Income (Loss)	\$	1,377	\$	(706)	
Depreciation and Amortization*		396		268	
Stock-based compensation expense		589		108	
Restructuring/severance		-		318	
Interest expense and other (gain), net		(76)		9	
Non-cash lease expense***		183		-	
Income tax expense		605		(384)	
Adjusted EBITDA	\$	3,074	\$	(387)	
% of Net Revenue		10%		(2%)	

	For The Three Months Ended September 30,			
	2022		2021	
Adjusted EBITDA:				
Net Income (Loss)	\$	4,873	\$	6,107
Depreciation and Amortization*		418		201
Stock-based compensation expense		578		532
Restructuring/severance		-		-
Interest expense and other (gain), net		206		18
Non-cash lease expense***		572		553
Income tax expense		1,479		1,921
Adjusted EBITDA	\$	8,126	\$	9,332
% of Net Revenue		20%		27%

	For The Three Months Ended June 3			
		2022		2021
Adjusted EBITDA:				
Net Income (Loss)	\$	3,346	\$	2,808
Depreciation and Amortization*		411		242
Stock-based compensation expense		535		401
Restructuring/severance		-		-
Interest expense and other (gain), net		215		45
Non-cash lease expense***		227		303
Income tax expense		803		962
Adjusted EBITDA	\$	5,537	\$	4,761
% of Net Revenue		15%		15%

	For	For The Three Months Ended December 31,			
	2022		2021		
Adjusted EBITDA:					
Net Income (Loss)	\$	7,452	\$	8,894	
Depreciation and Amortization*		423		214	
Stock-based compensation expense		640		589	
Restructuring/severance		-		-	
Interest expense and other (gain), net		395		23	
Non-cash lease expense***		183		572	
Income tax expense		2,263		2,669	
Adjusted EBITDA		11,356	\$	12,961	
% of Net Revenue		23%		32%	

EBITDA Reconciliation - 2021

	For The Three Months Ended March 31,			
		2021		2020
Adjusted EBITDA:				
Net Income (Loss)	\$	(706)	\$	2,937
Depreciation and Amortization*		268		68
Stock-based compensation expense		108		497
Restructuring/severance		318		-
Interest expense and other (gain), net		9		4
Non-cash lease expense***		-		-
Income tax expense	_	(384)		(483)
Adjusted EBITDA	\$	(387)	\$	3,023
% of Net Revenue		(2%)		20%

	For The Three Months Ended September 3			
	2021		2	2020
Adjusted EBITDA:				
Net Income (Loss)	\$	6,107	\$	1,333
Depreciation and Amortization*		201		305
Stock-based compensation expense		532		730
Restructuring/severance		-		-
Interest expense and other (gain), net		18		5
Non-cash lease expense***		553		-
Income tax expense		1,921		71
Adjusted EBITDA	\$	9,332	\$	2,444
% of Net Revenue		27%		12%

		For The Three Months Ended June 30,			
		2021		2020	
Adjusted EBITDA:					
Net Income (Loss)	\$	2,808	\$	3,017	
Depreciation and Amortization*		242		97	
Stock-based compensation expense		401		579	
Restructuring/severance		-		-	
Interest expense and other (gain), net		45		5	
Non-cash lease expense***		303		-	
Income tax expense		962		1,063	
Adjusted EBITDA	\$	4,761	\$	4,761	
% of Net Revenue		15%		25%	

	For The Three Months Ended December 31,			
	2021		2020	
Adjusted EBITDA:				
Net Income (Loss)	\$	8,894	\$	1,788
Depreciation and Amortization*		214		272
Stock-based compensation expense		589		875
Restructuring/severance		-		-
Interest expense and other (gain), net		23		82
Non-cash lease expense***		572		-
Income tax expense		2,669		428
Adjusted EBITDA	\$	12,961	\$	3,445
% of Net Revenue		32%		13%